These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 23287571)

  • 1. Hsp90: still a viable target in prostate cancer.
    Centenera MM; Fitzpatrick AK; Tilley WD; Butler LM
    Biochim Biophys Acta; 2013 Apr; 1835(2):211-8. PubMed ID: 23287571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
    Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM
    Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms.
    Centenera MM; Carter SL; Gillis JL; Marrocco-Tallarigo DL; Grose RH; Tilley WD; Butler LM
    Endocr Relat Cancer; 2015 Oct; 22(5):805-18. PubMed ID: 26187127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells.
    Eskew JD; Sadikot T; Morales P; Duren A; Dunwiddie I; Swink M; Zhang X; Hembruff S; Donnelly A; Rajewski RA; Blagg BS; Manjarrez JR; Matts RL; Holzbeierlein JM; Vielhauer GA
    BMC Cancer; 2011 Oct; 11():468. PubMed ID: 22039910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The promise of heat shock protein inhibitors in the treatment of castration resistant prostate cancer.
    Ischia J; Saad F; Gleave M
    Curr Opin Urol; 2013 May; 23(3):194-200. PubMed ID: 23385973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 17-DMCHAG, a new geldanamycin derivative, inhibits prostate cancer cells through Hsp90 inhibition and survivin downregulation.
    Wang J; Li Z; Lin Z; Zhao B; Wang Y; Peng R; Wang M; Lu C; Shi G; Shen Y
    Cancer Lett; 2015 Jun; 362(1):83-96. PubMed ID: 25813406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
    Powers MV; Workman P
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S125-35. PubMed ID: 17259553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heat-shock protein 90 (Hsp90) as anticancer target for drug discovery: an ample computational perspective.
    Kumalo HM; Bhakat S; Soliman ME
    Chem Biol Drug Des; 2015 Nov; 86(5):1131-60. PubMed ID: 25958815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
    Workman P
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lead generation of heat shock protein 90 inhibitors by a combination of fragment-based approach, virtual screening, and structure-based drug design.
    Miura T; Fukami TA; Hasegawa K; Ono N; Suda A; Shindo H; Yoon DO; Kim SJ; Na YJ; Aoki Y; Shimma N; Tsukuda T; Shiratori Y
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5778-83. PubMed ID: 21875802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenomics in cancer drug discovery and development: inhibitors of the Hsp90 molecular chaperone.
    Workman P
    Cancer Detect Prev; 2002; 26(6):405-10. PubMed ID: 12507224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy.
    Porter JR; Fritz CC; Depew KM
    Curr Opin Chem Biol; 2010 Jun; 14(3):412-20. PubMed ID: 20409745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell surface heat shock protein 90 modulates prostate cancer cell adhesion and invasion through the integrin-β1/focal adhesion kinase/c-Src signaling pathway.
    Liu X; Yan Z; Huang L; Guo M; Zhang Z; Guo C
    Oncol Rep; 2011 May; 25(5):1343-51. PubMed ID: 21369706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Inhibitors of the heat shock protein 90 activity: a novel class of tumor radiosensitizers].
    Kabakov AE; Kudriavtsev VA; Makarova IuM
    Radiats Biol Radioecol; 2010; 50(5):528-35. PubMed ID: 21261003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010.
    Messaoudi S; Peyrat JF; Brion JD; Alami M
    Expert Opin Ther Pat; 2011 Oct; 21(10):1501-42. PubMed ID: 21689065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
    Kim T; Keum G; Pae AN
    Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Heat shock protein 90: novel target for cancer therapy].
    Chen Y; Ding J
    Ai Zheng; 2004 Aug; 23(8):968-74. PubMed ID: 15301726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2,4-dihydroxy benzaldehyde derived Schiff bases as small molecule Hsp90 inhibitors: rational identification of a new anticancer lead.
    Dutta Gupta S; Revathi B; Mazaira GI; Galigniana MD; Subrahmanyam CV; Gowrishankar NL; Raghavendra NM
    Bioorg Chem; 2015 Apr; 59():97-105. PubMed ID: 25727264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
    Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF
    J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer.
    Moser C; Lang SA; Stoeltzing O
    Anticancer Res; 2009 Jun; 29(6):2031-42. PubMed ID: 19528462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.